GlassScriptPhysician profile
Alisha Brooke Smith
NPI 1487900668
$2,052.74
in general payments reported to CMS, 2019-2025
14 companies · $882 in 2025
The $882 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.09 · 2022: $162 · 2023: $538 · 2024: $406 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $646.07 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $399.71 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $277.63 | 2022-2025 | Wegovy, Saxenda, Rybelsus |
| Glaxosmithkline, LLC. | $249.19 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $128.11 | 2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $82.92 | 2023-2025 | Cologuard Collection Kit |
| Halozyme INC | $57.90 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.07 | 2024-2025 | Jardiance |
| Amgen INC. | $38.19 | 2025 | Repatha, Otezla |
| Abbott Laboratories | $33.65 | 2024 | Freestyle Libre 3 |
| Lundbeck LLC | $29.35 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $23.68 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $18.27 | 2024 | |
| Biomerieux INC | $16.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisha Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.